Vanda Pharmaceuticals Granted FDA Orphan Drug Designation For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S)
Portfolio Pulse from Charles Gross
Vanda Pharmaceuticals has been granted FDA Orphan Drug Designation for the treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S). This designation provides various benefits, including tax credits and market exclusivity.
May 31, 2023 | 11:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vanda Pharmaceuticals' FDA Orphan Drug Designation for CMT2S treatment may lead to increased investor interest and potential stock price growth.
The FDA Orphan Drug Designation provides various benefits to Vanda Pharmaceuticals, including tax credits, market exclusivity, and potential grant funding. This news may attract investor interest and lead to stock price growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100